Bavarian Nordic stock
Price history
+29.10% over the period1 year: from kr 184.05 (November 17, 2025) to kr 237.60 (November 16, 2026), +29.10%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 237.60 |
| October 30, 2026 | kr 245.40 |
| September 30, 2026 | kr 221.00 |
| August 31, 2026 | kr 217.60 |
| July 31, 2026 | kr 177.90 |
| June 30, 2026 | kr 182.70 |
| May 29, 2026 | kr 187.40 |
| April 30, 2026 | kr 187.20 |
| March 31, 2026 | kr 193.05 |
| February 27, 2026 | kr 197.50 |
| January 30, 2026 | kr 192.00 |
| December 30, 2025 | kr 190.85 |
| November 28, 2025 | kr 184.75 |
| November 17, 2025 | kr 184.05 |
At a glance
The company
Develop, manufacture and supply life-saving vaccines for smallpox, monkeypox, rabies, tick-borne encephalitis, cholera and typhoid fever
Latest results
Quarter to June 30, 2026 · EPS kr 9.40 (estimate kr 4.50)
TickerLandia's take on Bavarian Nordic
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 13 vs a median of 23 over its last 6 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 12 vs 17 (−29%) in a group of 9.
- Strong point: Financial strength (82/100 in its group). Weak point: Profitability (48/100).
- “Below historical valuation” (Denmark): No. 3 of 4.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.55% from the 52-week high
Analysts · 4 analysts
Average targetkr 291.25+22.58% vs. price
Buy 4 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Bavarian Nordic
Compared with similar companies: very low price and very high financial strength.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low13
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 12.2 14 Forward P/E 19.8 30 Price/sales 2.79 6 EV/EBITDA 8.86 9 Price/book 1.36 8 Profitabilityaverage48
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 18.1% 47 Net margin 24.3% 66 ROE 12.2% 57 Gross margin 50.2% 22 ROA 5.0% 49 Earnings stabilityaverage56
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 18.5% 58 Loss-making yearscounts in reverse: lower means more earnings stability 2 of 5 annual reports 53 Growthhigh67
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +25.61% 57 Revenue growth (year over year) +23.20% 54 Earnings growth (year over year) +169.70% 88 Financial strengthvery high82
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.96 80 Interest coverage 167.4 82 Debt/equitycounts in reverse: lower means more financial strength 0.01 88 Current ratio 6.53 80 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong79
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +26.78% 71 Distance from 200-day average +18.93% 87 Risklow31
How much the price swings.
Metric Value Position in group Volatility (60 days) 26.8% 49 Maximum drawdown (12 months) 14.2% 12
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Bavarian Nordic is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Bavarian Nordic's P/E today is 13.5, below the median of its last 6 fiscal years (23.1; between 9.24 and 197.0 from 2016 to 2025). Bavarian Nordic's P/E (trailing 12 months): 12.2, −29% against the median of a group of 9 similar companies (17.1).
Compared with 9 similar companies
| Metric | Bavarian Nordic | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 12.2 | Middle | |
| Forward P/E | 19.8 | Middle | |
| Operating margin | 18.1% | Low | |
| ROE | 12.2% | Middle | |
| Debt/equity | 0.01 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Bavarian Nordic. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 2.03B
Latest quarter · Q2 2026
Net income
kr 731.64M
Latest quarter · Q2 2026
Quarterly net margin
36.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 17.7B
- P/E
- 12.2
- EPS
- kr 19.50
- Volume
- 298.21K
- Daily trading
- €6.18M
- Dividend yield
- 0.00%
How Bavarian Nordic is changing
All resultsRevenue grew 27.5% a year on average over the last 5 years
Operating margin rose from −2.2% to 16.6%
Profits turn into cash: free cash flow equal to 140% of net income
Returns
Bavarian Nordic returns
kr 1,000 invested in Bavarian Nordic 5 years ago, on November 16, 2021, would be worth kr 759 today: −24.11% in total, −5.37% per year. This is the price return only: dividends are excluded.
| Period | Bavarian Nordic | kr 1,000 becomes |
|---|---|---|
| 1 month | +0.25% | kr 1,003 |
| 6 months | +26.18% | kr 1,262 |
| Year to date | +24.50% | kr 1,245 |
| 1 year | +29.10% | kr 1,291 |
| 3 years | +66.85% | kr 1,669 |
| 5 years | −24.11% | kr 759 |
| 10 years | +27.27% | kr 1,273 |
Price only, without dividends. Calculate your investment
The chart in detail
Bavarian Nordic: technical analysis
Bavarian Nordic is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 40.9% below its all-time closing high (kr 401.70, August 3, 2022).
- Trend
- Upward
- RSI (14 sessions)
- 48
- Between 30 and 70
- vs 200-session average
- +19.00%
Support and resistance
Price areas where Bavarian Nordic has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last pricekr 237.60
- Supportkr 223.40−5.98%2 touches, last on September 23, 2026
- Supportkr 202.90−14.60%3 touches, last on May 12, 2026
- Supportkr 198.98−16.25%5 touches, last on September 15, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 26.6%
- Largest fall in the last year
- −14.18%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Bavarian Nordic: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Bavarian Nordic has been April: +6.50% on average, positive in 17 years out of 27. The weakest has been September: −5.98% on average, positive in 12 years out of 27. November, the current month, has been positive in 11 years out of 26 (+0.65% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.71% | +2.99% | 17 of 26 |
| February | +0.02% | +0.55% | 15 of 27 |
| March | +0.52% | −2.25% | 10 of 27 |
| April | +6.50% | +3.11% | 17 of 27 |
| May | +5.75% | +3.02% | 17 of 27 |
| June | −3.23% | −3.88% | 6 of 27 |
| July | +4.71% | +3.35% | 18 of 27 |
| August | +0.09% | −2.73% | 11 of 27 |
| September | −5.98% | −3.47% | 12 of 27 |
| October | +3.58% | +0.40% | 14 of 27 |
| November | +0.65% | −1.17% | 11 of 26 |
| December | +0.64% | +1.18% | 14 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Bavarian Nordic and its competitors
Employing 1,906 people, the company develops and supplies vaccines against infectious diseases, with its portfolio centred on smallpox and monkeypox vaccines sold as JYNNEOS, IMVANEX and IMVAMUNE. Other products include a rabies vaccine marketed as Rabipur and RabAvert, the tick-borne encephalitis vaccine Encepur, and two oral vaccines, Vaxchora against cholera and Vivotif/Typhoral against typhoid fever. Sales and operations span the United States, Canada, several European countries, Japan, Singapore, Taiwan, Saudi Arabia and Australia, and the company is also developing MVA-BN WEV, a candidate under study for encephalitis viruses.
- Headquarters
- Hellerup, Denmark
- Employees
- 1,906
- Founded
- 1992
- Chief executive
- Paul Chaplin
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Bavarian NordicBAVA | $2.62B | 18.1% | 12.2 | +26.18% |
| BioArcticBIOA.B | $2.74B | 19.6% | 262.7 | −3.82% |
| Zealand PharmaZEAL | $2.37B | 59.0% | 5.49 | −20.61% |
| Lakefront BiotherapeuticsLKFT | $2.2B | 57.5% | 3.21 | +33.42% |
| CamurusCAMX | $4.41B | 37.4% | 58.9 | +46.61% |
| Pharma MarPHM | $1.28B | 21.3% | 17.1 | −29.91% |
Same industry or related industries, similar size. Compare Bavarian Nordic with its competitors · Full profile
